REGN Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of 32.59%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Eli Lilly and's return on equity of 80.24%.

Regeneron Pharmaceuticals has a consensus price target of $923.05, signalling upside risk potential of 39.64%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 16.83%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Regeneron Pharmaceuticals has a beta of 0.270, which suggesting that the stock is 72.991% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.13%. Eli Lilly and offers a yield of 0.62% to investors and pays a quarterly dividend of $1.50 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Regeneron Pharmaceuticals's net income of $917.7M is lower than Eli Lilly and's net income of $4.4B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.27x while Eli Lilly and's PE ratio is 73.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.36x versus 17.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of 23.96%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Merck &'s return on equity of 40.25%.

Regeneron Pharmaceuticals has a consensus price target of $923.05, signalling upside risk potential of 39.64%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 21.4%. Given that Regeneron Pharmaceuticals has higher upside potential than Merck &, analysts believe Regeneron Pharmaceuticals is more attractive than Merck &.

Regeneron Pharmaceuticals has a beta of 0.270, which suggesting that the stock is 72.991% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.13%. Merck & offers a yield of 3.42% to investors and pays a quarterly dividend of $0.81 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are smaller than Merck & quarterly revenues of $15.6B. Regeneron Pharmaceuticals's net income of $917.7M is lower than Merck &'s net income of $3.7B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.27x while Merck &'s PE ratio is 13.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.36x versus 3.66x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of -117.16%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Moderna's return on equity of -29.09%.

Regeneron Pharmaceuticals has a consensus price target of $923.05, signalling upside risk potential of 39.64%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 56.4%. Given that Moderna has higher upside potential than Regeneron Pharmaceuticals, analysts believe Moderna is more attractive than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has a beta of 0.270, which suggesting that the stock is 72.991% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.13%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are larger than Moderna quarterly revenues of $956M. Regeneron Pharmaceuticals's net income of $917.7M is higher than Moderna's net income of -$1.1B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.27x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.36x versus 4.14x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 24.22% compared to Regeneron Pharmaceuticals's net margin of 2.31%. Regeneron Pharmaceuticals's return on equity of 15.78% beat Pfizer's return on equity of 8.91%.

Regeneron Pharmaceuticals has a consensus price target of $923.05, signalling upside risk potential of 39.64%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 19.56%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Regeneron Pharmaceuticals has a beta of 0.270, which suggesting that the stock is 72.991% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.13%. Pfizer offers a yield of 6.47% to investors and pays a quarterly dividend of $0.43 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3.8B, which are smaller than Pfizer quarterly revenues of $17.8B. Regeneron Pharmaceuticals's net income of $917.7M is higher than Pfizer's net income of $410M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 17.27x while Pfizer's PE ratio is 18.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 5.36x versus 2.34x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.